PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33053283-10	2020	CONCLUSIONS: In patients with rheumatoid arthritis refractory to biologic DMARDs, upadacitinib was superior to abatacept in the change from baseline in the DAS28-CRP and the achievement of remission at week 12 but was associated with more serious adverse events.	upadacitinib	82-94	C-reactive protein	Homo sapiens	162-165	
35141743-5	2022	RESULTS: Over 12 weeks, the median NNT and the median CPR to achieve DAS28-CRP remission were 4.3 and JPY 1,799,696 (USD 16,361), respectively, for upadacitinib 15mg + csDMARD.	upadacitinib	148-160	C-reactive protein	Homo sapiens	75-78	
35142908-4	2022	The filgotinib 200 mg + MTX and upadacitinib 15 mg + MTX groups showed a significantly higher DAS28-CRP < 2.6 than adalimumab 40 mg + MTX.	upadacitinib	32-44	C-reactive protein	Homo sapiens	100-103